<DOC>
	<DOCNO>NCT02249663</DOCNO>
	<brief_summary>To evaluate therapeutic equivalence test formulation Azelastine hydrochloride Fluticasone propionate Nasal Spray reference list drug , Dymista™ Nasal Spray relief sign symptoms Seasonal Allergic Rhinitis .</brief_summary>
	<brief_title>Clinical Equivalence Azelastine Hydrochloride Fluticasone Propionate , 137/50 mcg Nasal Spray Dymista™</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>Male nonpregnant , nonlactating female 12 year age old . Signed informed consent form , meet criteria current FDA regulation . For patient age majority state study conduct ( 18 year state ) parent legal guardian sign consent form child require sign patient `` assent '' form write way understandable child . Documented positive allergic skin test , perform within previous 12 month , one allergens season time study conduct . A minimum two consecutive year previous history Seasonal Allergic Rhinitis ( SAR ) pollen/allergen season time study conduct . Eligibility requirement placebo leadin period : A total ( composite ) score least 6 reflective Total Nasal Symptom Score ( rTNSS ) minimum least 2 `` nasal congestion '' minimum score least 2 one remain 3 symptom total ( composite ) score least 4 reflective Total Ocular Symptom Score ( rTOSS ) . These score represent 12 hour screen visit . In addition requirement , patient follow end placebo leadin period randomization : 1 ) average composite score least 6 rTNSS minimum average score least 2 `` nasal congestion '' minimum average score least 2 one remain 3 symptom , 2 ) average composite score least 4 rTOSS . These score represent 3 day 7 day placebo runin period Randomization visit morning first day Randomization visit . Under 12 year age . Females pregnant , lactating , likely become pregnant study . Negative lack document skin allergen test ( perform within previous 12 month ) least one allergens season time study conduct . The result positive skin allergen test result report . Patients suffer chronic sign symptom Perennial Allergic Rhinitis ( PAR ) exclude study unless Investigator assess patient 's current sign symptom clear exacerbation Seasonal Allergic Rhinitis ( SAR ) rather chronic PAR . Patients suffer PAR SAR different allergen season time study conduct . Previous history le 2 year SAR pollen/allergen season time study conduct . Before placebo leadin period , patient total score le 6 rTNSS score less 2 `` nasal congestion '' . Any patient meet minimum individual nasal symptom score requirement start placebo leadin period long meet requirement prior randomize active treatment period study continue active treatment period . At end placebo leadin period randomization , patient average composite score less 6 rTNSS average composite score less 4 rTOSS . History asthma previous 2 year require chronic therapy . Occasional acute mild exercise induce asthma allowable condition treatment attack restrict betaagonists . Patients nasal condition , include infectious rhinitis , rhinitis medicamentosa , atrophic rhinitis . Clinically significant nasal deformity recent nasal surgery trauma completely heal . Sinus infection within previous 30 day history reoccurring sinus infection . Patient start immunotherapy change dose immunotherapy within 30 day first placebo leadin dose likely start immunotherapy , change current dose study . Treatment oral Candidiasis within 30 day start study current oral Candidiasis infection . Upper respiratory tract infection within previous 30 day . Patients history tuberculosis . Patients presence glaucoma , cataract , ocular herpes simplex , conjunctivitis , eye infection relate diagnosis SAR within 14 day enrollment . The patient recent exposure ( 30 day ) risk expose chicken pox measles . Patients untreated fungal , bacterial , systemic viral infection within previous 30 day . Use ophthalmic steroid within 14 day nasal , inhale , systemic steroid within 30 day study start . Super high potency topical steroid use study . Use medication significantly inhibit cytochrome P450 subfamily enzyme CYP3A4 . Use intranasal systemic secondgeneration antihistamine within 10 day enrollment . Use intranasal cromolyn within 14 day enrollment . Use intranasal systemic firstgeneration antihistamine , leukotriene receptor antagonsits nasal decongestant within 3 day enrollment . Use tricyclic antidepressant within 30 day enrollment . Patients attentiondeficit disorder treat methylphenidate containing product stable regimen least 30 previous day remain dose throughout study . Desensitization therapy seasonal allergen cause patient 's allergic rhinitis within previous 6 month . Previous SAR and/or PAR proven unresponsive steroid therapy . Any known hypersensitivity azelastine hydrochloride , fluticasone propionate , steroid , component study nasal spray . Significant history current evidence chronic infectious disease , system disorder , organ disorder , medical condition Investigator 's opinion would place patient undue risk participate could jeopardize integrity study evaluation . Receipt drug part research study within 30 day prior first placebo leadin dose . Planned travel outside local area 2 consecutive day 3 day total , patient 's participation study . Previous participation study . The patient history noncompliance medication regimens treatment protocol previous clinical study . The patient member investigational study staff member family investigational study staff . The patient currently smoke cigarette , cigar , and/or pipe heavy smoker ( example , average 10 cigarette per day ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>